开发和评估多功能性酸结合亚洲酸纳米构造,以缓解阿尔茨海默病的认知缺陷
Tripti Halder1,2, Bijit Saha3, Namdev Dhas4
1Department of Pharmacognosy, Nirma University, Ahmedabad, Gujarat, India.
Drug development research
|February 13, 2024
概括
酸 (SA) 改性纳米结构脂质载体 (NLCs) 在阿尔茨海默氏症 (AD) 治疗中显示出前景. 这些NLC在临床前模型中有效地提供治疗剂,减少了AD的特征,并改善了认知功能.
科学领域:
- 神经科学是一个神经科学.
- 纳米技术纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 酸 (SA) 对于神经元修复和认知功能至关重要.
- 亚酸作为一个连接体,促进治疗剂的向输送.
- 阿尔茨海默病 (AD) 的特点是神经退行和认知能力下降.
研究的目的:
- 开发SA表面修饰的纳米结构脂质载体 (NLCs) 进行有针对性的输送.
- 评估SA-NLCs在体外和体内的神经保护和治疗潜力.
- 评估SA-NLCs在缓解AD特征和认知缺陷方面的有效性.
主要方法:
- 碳胺结合法用于NLCs的SA表面修改.
- 使用DSC,FTIR和XPS进行表征.
- 在SH-SY5Y和hCMEC/D3细胞中的体外神经保护试验.
- 在注射β-粉胺的老鼠身上进行了体内药学动力学研究.
主要成果:
- 通过表征研究证实了SA与NLC的成功结合.
- 在神经元和内皮细胞系中观察到显著的体外神经保护作用.
- 在体内研究表明,阿尔茨海默病的特征 (Aβ1-42),tau,GSK-3β,IL-6,TNF-α) 的减少.
- 在28天后恢复胆固醇功能 (AChE,BuChE水平) 和认知能力的改善.
结论:
- 经SA修改的NLC对治疗剂的向输送是有效的.
- 发育的NLCs对AD病理学具有显著的神经保护和治疗潜力.
- 这些发现支持SA-NLCs作为缓解阿尔茨海默病认知缺陷的有希望的战略.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
125
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
125
Alzheimer's Disease: Treatment
189
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
189
Alzheimer's Disease: Overview
484
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
484


